Probing integrin selectivity:: Rational design of highly active and selective ligands for the α5β1 and αvβ3 integrin receptor

被引：81
作者：
Heckmann, Dominik
Meyer, Axel
Marinelli, Luciana
Zahn, Grit
Stragies, Roland
Kessler, Horst
机构：
[1] Tech Univ Munich, Dept Chem, D-85747 Garching, Germany
[2] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[3] Jerini AG, D-10115 Berlin, Germany
来源：
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2007年 / 46卷 / 19期
关键词：
antitumor agents; drug design; integrin ligands; receptors; structure-activity relationships;
D O I：
10.1002/anie.200700008
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
(Chemical Equation Presented) Try and fit in: A strategy for the rational design of α5β1 ligands for the purpose of lead generation and biochemical studies on integrin selectivity is based α5β1 homology modeling. Ligand 1 can bind α5β1 with activities in the subnanomolar range and high selectivity. Minor changes can result in a ligand with a high selectivity for the related αvβ3 receptor. © 2007 Wiley-VCH Verlag GmbH & Co. KGaA.
引用
收藏
页码：3571 / 3574
页数：4
相关论文
共 31 条
[1]   ARG-GLY-ASP CONSTRAINED WITHIN CYCLIC PENTAPEPTIDES - STRONG AND SELECTIVE INHIBITORS OF CELL-ADHESION TO VITRONECTIN AND LAMININ FRAGMENT-P1 [J].
AUMAILLEY, M ;
GURRATH, M ;
MULLER, G ;
CALVETE, J ;
TIMPL, R ;
KESSLER, H .
FEBS LETTERS, 1991, 291 (01) :50-54
[2]   Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins [J].
Bader, BL ;
Rayburn, H ;
Crowley, D ;
Hynes, RO .
CELL, 1998, 95 (04) :507-519
[3]   INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].
BROOKS, PC ;
MONTGOMERY, AMP ;
ROSENFELD, M ;
REISFELD, RA ;
HU, TH ;
KLIER, G ;
CHERESH, DA .
CELL, 1994, 79 (07) :1157-1164
[4]   Integrin antagonists [J].
Curley, GP ;
Blum, H ;
Humphries, MJ .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 56 (5-6) :427-441
[5]   N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists [J].
Dechantsreiter, MA ;
Planker, E ;
Mathä, B ;
Lohof, E ;
Hölzemann, G ;
Jonczyk, A ;
Goodman, SL ;
Kessler, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) :3033-3040
[6]  
GEORGE EL, 1993, DEVELOPMENT, V119, P1079
[7]  
Gibson C, 2001, ANGEW CHEM INT EDIT, V40, P165, DOI 10.1002/1521-3773(20010105)40:1<165::AID-ANIE165>3.0.CO
[8]  
2-8
[9]  
Gibson C., 2001, ANGEW CHEM, V113, P169
[10]  
Gottschalk KE, 2002, ANGEW CHEM INT EDIT, V41, P3767, DOI 10.1002/1521-3773(20021018)41:20<3767::AID-ANIE3767>3.0.CO
1234